Invivyd (IVVD) Operating Expenses (2021 - 2026)
Invivyd's (IVVD) quarterly Operating Expenses came in at $29.8 million in Q4 2025, down 9.95% YoY from $33.0 million in Q4 2024, and up 23.23% on a QoQ basis from $24.2 million in Q3 2025.
Invivyd (IVVD) Operating Expenses (2021 - 2026) Analysis & Trends
Invivyd (IVVD) has 5 years of Operating Expenses data on file, last reported at $29.8 million in Q4 2025.
- Quarterly Operating Expenses fell 9.95% year-over-year to $29.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $109.0 million (down 46.12% YoY) and the FY2025 annual result came in at $109.0 million, down 46.12% from the prior year.
- Operating Expenses climbed to $29.8 million in Q4 2025, from $24.2 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $100.7 million in Q1 2022 to a low of $24.2 million in Q3 2025.
- A 5-year average of $49.9 million and a median of $46.7 million in 2022 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses soared 160.25% — and 2025, when it slumped 66.27%.
- Tracing IVVD's Operating Expenses over 5 years: stood at $83.1 million in 2021, then plunged by 41.98% to $48.2 million in 2022, then surged by 59.2% to $76.8 million in 2023, then plunged by 56.94% to $33.0 million in 2024, then dropped by 9.95% to $29.8 million in 2025.
- The last three Operating Expenses figures came in at $29.8 million (Q4 2025), $24.2 million (Q3 2025), and $26.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Invivyd | 212.23 Mn | 52.15 Mn | 13.01 Mn | 60.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.11 Mn |
| Dec 31, 2025 | 29.76 Mn |
| Sep 30, 2025 | 24.15 Mn |
| Jun 30, 2025 | 26.85 Mn |
| Mar 31, 2025 | 28.23 Mn |
| Dec 31, 2024 | 33.05 Mn |
| Sep 30, 2024 | 71.61 Mn |
| Jun 30, 2024 | 51.51 Mn |
| Mar 31, 2024 | 46.09 Mn |
| Dec 31, 2023 | 76.75 Mn |
| Sep 30, 2023 | 43.06 Mn |
| Jun 30, 2023 | 53.88 Mn |
| Mar 31, 2023 | 39.07 Mn |
| Dec 31, 2022 | 48.21 Mn |
| Sep 30, 2022 | 47.33 Mn |
| Jun 30, 2022 | 51.75 Mn |
| Mar 31, 2022 | 100.74 Mn |
| Dec 31, 2021 | 83.09 Mn |
| Sep 30, 2021 | 60.42 Mn |
| Jun 30, 2021 | 44.69 Mn |